###begin article-title 0
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
SERPING1 polymorphisms in polypoidal choroidal vasculopathy
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 140 148 140 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 205 208 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
To investigate whether common genetic variants in the complement component 1 inhibitor gene (serpin peptidase inhibitor, clade G, member 1, SERPING1) are associated with polypoidal choroidal vasculopathy (PCV) in a Chinese Han population.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 194 202 194 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 35 38 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
DNA samples were obtained from 118 PCV patients and 115 healthy subjects. Data derived from the HapMap project were used to select tag single nucleotide polymorphisms (SNPs) across the extended SERPING1 region. A previously reported age-related macular degeneration-related risk factor () was forcibly included. Genotyping of each tag SNP was performed by PCR restriction fragment length polymorphism and direct DNA sequencing techniques.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 105 108 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 254 257 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Four SNPs for SERPING1, , , , and , were chosen as tag SNPs. None of these tag SNPs were associated with PCV, according to the single-SNP association test (p=0.41-0.83). Evaluation of common haplotypes across SERPING1 did not reveal any association with PCV (p=0.49-0.82).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 123 126 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
We found no evidence to support the role of any common SERPING1 variants, including the  variant, in the susceptibility to PCV in a Chinese Han population.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 469 470 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 35 38 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 244 247 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Polypoidal choroidal vasculopathy (PCV) is a hemorrhagic and exudative macular disease that shows distinct forms of choroidal vascular abnormalities, including abnormal choroidal vascular networks and polypoidal lesions at their borders [1-3]. PCV has a particularly high incidence among the exudative age-related macular degeneration (AMD) in Asian populations, accounting for 24.5% of exudative AMD in the Chinese population [4] and 54.7% in the Japanese population [5] compared with only 8%-13% in Caucasians [3].
###end p 10
###begin p 11
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 370 373 370 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 485 490 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 0 3 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 153 156 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 208 211 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 635 638 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
PCV shares many similarities with neovascular AMD, including demography [4,5], pathology [6-8], and manifestation [4,5]. Due to the similarities between PCV and neovascular AMD, most genetic risk factors for PCV were found based on previous genetic studies for AMD patients. Several genetic risk factors for AMD have been established, including the complement factor H (CFH) gene on chromosome 1q32 [9-13] and two tightly linked genes, namely age-related maculopathy susceptibility 2 (ARMS2) and high-temperature requirement factor A1 (HTRA1) on chromosome 10q26 [14-16]. Several recent studies have shown a strong association between PCV and these variants [17-22].
###end p 11
###begin p 12
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 273 275 273 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB</italic>
###xml 335 337 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 370 372 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C1</italic>
###xml 448 458 448 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(SERPING1)</italic>
###xml 553 561 553 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 717 720 717 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3b</italic>
###xml 751 754 751 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB</italic>
###xml 758 761 758 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3b</italic>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 871 879 871 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
Since the discovery of the association between AMD and variants in CFH, several other genes regulating or involved in the alternative pathway of complement activation have been found to show a strong association with AMD, including those coding for complement component 3 (C3) [23], complement factor B (CFB), and complement factor 2 (C2) [24]. The complement factor 1 (C1) inhibitor is encoded by the serpin peptidase inhibitor, clade G, member 1 (SERPING1) gene (GenBank ) and is a member of a large family of serine proteases. The protein encoded by SERPING1 is a key regulator of the classical pathway for complement activation. It has been reported to downregulate the alternative pathway in vitro by binding to C3b and inhibiting the binding of CFB to C3b [25]. Recently, Ennis et al. reported a protective effect on AMD for the minor allele of  within intron 6 of SERPING1 [26]. However, the association was not replicated in another study conducted by Park et al. [27].
###end p 12
###begin p 13
###xml 104 107 104 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 151 159 151 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 402 410 402 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 37 40 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 96 99 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 250 253 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 475 478 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Considering the similarities between PCV and neovascular AMD and the strong association between PCV and CFH, we hypothesized that polymorphisms in the SERPING1 gene, another regulator of the complement system, might play a role in the development of PCV. In this study, we genotyped four tag single nucleotide polymorphisms (SNPs) that are highly representative of the common genetic variations in the SERPING1 region and analyzed the associations between these variants and PCV in a Chinese Han population.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 15
###begin p 16
The study protocol was approved by the institutional review board at the Zhongshan Ophthalmic Center of Sun Yat-sen University, Guangzhou, China, and performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects before participation in this study. All cases and controls included in this study were Chinese Han individuals recruited from the Zhongshan Ophthalmic Center.
###end p 16
###begin p 17
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 742 750 742 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1016 1023 1016 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 4 7 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 241 244 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 385 388 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 461 464 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 569 572 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 761 769 <span type="species:ncbi:9606">Patients</span>
All PCV patients underwent ophthalmic examinations, including visual acuity measurements, slit-lamp biomicroscopy, ophthalmoscope, color fundus photographs, fluorescein angiography, and indocyanine green angiography (ICGA). The diagnosis of PCV was based on identification of polypoidal choroidal vascular dilations with or without branching inner choroidal vessels on ICGA. Thus, all PCV patients enrolled in this study met the criteria of definitive cases of PCV, as proposed by the Japanese Study Group of Polypoidal Choroidal Vasculopathy [28]. Definitive cases of PCV must satisfy at least one of the following two criteria: (1) protruding orange-red lesions visible on fundus examination; (2) characteristic polypoidal lesions evident (Figure 1) on ICGA. Patients with other neovascularized maculopathies, such as neovascular AMD, pathologic myopia, angioid streaks, presumed ocular histoplasmosis, and retinal angiomatous proliferation, were excluded. The characteristics of the study group are summarized in Table 1.
###end p 17
###begin p 18
###xml 60 61 60 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 229 230 229 230 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 54 57 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 92 99 <span type="species:ncbi:9606">patient</span>
###xml 105 108 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 249 252 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Clinical photos of polypoidal choroidal vasculopathy (PCV). A: Color fundus photograph of a patient with PCV. Several orange lesions are visible in the macula. Hemorrhage is visible between the orange lesions and the optic disk. B: The diagnosis of PCV was confirmed with indocyanine green angiography (ICGA). Abnormal choroidal vascular networks and characteristic polypoidal lesions are visible in the macula, corresponding to the orange lesion in the color fundus photograph.
###end p 18
###begin title 19
Characteristics of the study population
###end title 19
###begin p 20
###xml 15 18 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Abbreviations: PCV represents Polypoidal Choroidal Vasculopathy; SD represents standard deviation.
###end p 20
###begin p 21
All control subjects underwent comprehensive ophthalmic examinations, and those with macular degeneration of any cause, macular changes (such as drusen or pigment abnormalities), or media opacities preventing clear visualization of the macula were excluded from the recruitment. All control subjects were unrelated to case subjects and were aged >/=50 years.
###end p 21
###begin title 22
Single nucleotide polymorphism selection
###end title 22
###begin p 23
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 331 332 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 379 380 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 633 640 633 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
SNPs across SERPING1, including 5 kb upstream and downstream in the international haplotype map (HapMap) [29] for the Han Chinese in Beijing, China (CHB), were used to select tag SNPs. SNPs with a minor allele frequency above 5% were evaluated for linkage disequilibrium (LD) using  [30]. A minimum threshold value of 0.8 for the r2 parameter was set in the Haploview software. r2 represents the multivariate coefficient of determination for all alleles that are to be captured. A previously reported SNP () was included as a tag SNP, using the forced inclusion option. The selected SNPs and SNPs captured by these SNPs are given in Table 2.
###end p 23
###begin title 24
Selected SNP and SNPS captured by these SNPS
###end title 24
###begin p 25
Abbreviations: SNP represents single nucleotide polymorphism.
###end p 25
###begin title 26
###xml 14 26 <span type="species:ncbi:9606">participants</span>
Genotyping of participants
###end title 26
###begin p 27
Peripheral blood sample were anticoagulated with ethylene diamine tetraacetic acid and stored at -80 degreesC before use. Genomic DNA from the blood by Nucleospin (R)Blood XL kit (Macherey-Nagel GmbH & Co., KG Duren, Germany). The kit contains a silica membrane which can specifically bind DNA. After binding, DNA can be washed out by elute buffer. Genotyping was performed using PCR restriction fragment length polymorphism and direct sequencing.
###end p 27
###begin p 28
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 308 315 308 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
The target DNA in SERPING1 was amplified by PCR using relevant primers. The primers for each SNP were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA). The primer sequences and restriction enzymes (New England Biolabs, Ipswich, MA) used for each SNP are presented in Table 3.
###end p 28
###begin title 29
Primers and restriction enzyme used in this study
###end title 29
###begin p 30
Abbreviations: NEB represents New England Biolabs, Ipswich, MA; SNP represents single nucleotide polymorphism; AT represents annealing temperature.
###end p 30
###begin p 31
###xml 325 332 311 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
Each PCR was performed in 20 mul of solution containing 10 mul of 2x Power Taq PCR MasterMix (Bioteke Corporation, Beijing, China), 8 pmol of primers, and 50 ng of genomic DNA. The cycling profile was: initial denaturation at 95 degreesC for 3 min, 33 cycles consisting of 95 degreesC for 30 s, proper annealing temperature (Table 3) for 30 s, 72 degreesC for 30 s, and a final extension for 10 min at 72 degreesC.
###end p 31
###begin p 32
###xml 583 585 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
The digestion conditions contained 7.25 mul pure water, 1 mul NEB buffer, 0.25 mul enzyme and 1.5 mul PCR product for enzyme BslI, BbvI, and DdeI. The reaction conditions contained 7.15 mul pure water, 1 mul NEB buffer, 0.1 mul BSA, 0.25 mul enzyme and 1.5 mul PCR product for enzyme BstNI. The reaction temperature for enzyme BslI was 55 degreesC, for enzyme BstNI was 60 degreesC, and for enzyme BbvI and DdeI was 37 degreesC. After digestion, all fragments were resolved by electrophoresis on 8% polyacrylamide gel (PAG) at 30 W for 2 h. Subsequently, the PAG was silver stained [31]. Briefly, the gels were fixed with 1% nitric acid for 5 min and 10% alcohol for 3min. After several changes of water, the gels were incubated in 0.1% silver nitrate for 25 min. Then the gels were developed in 3% sodium carbonate and the reaction was terminated with acetic acid. To confirm the accuracy of the method used, randomly selected subjects (10% of all samples) were analyzed by direct sequencing (Shanghai Sangon Biologic Engineering Technology & Service Co. Ltd. Shanghai, China). All the primers used for direct sequencing are available on request.
###end p 32
###begin title 33
Statistical analysis
###end title 33
###begin p 34
###xml 101 102 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 115 116 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 307 309 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 35 38 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Age and gender differences between PCV and control subjects were assessed using the unpaired Student t-test and chi2 test, respectively, with SPSS 13.0 for windows software (SPSS Inc., Chicago, IL). Deviations from the Hardy-Weinberg equilibrium were tested using the exact test implemented in the , v1.06 [32]. Genotypes and allele frequencies between cases and controls were evaluated for each SNP using the chi-square test with PLINK. The odds ratio (OR) and corresponding 95% confidence interval (CI) were calculated relative to the minor allele. Haploview software was used to assess LD patterns and haplotype association statistics. Haplotype blocks were determined using the "4-gamete rule" option implemented in Haploview. A p value of <0.05 was considered statistically significant.
###end p 34
###begin title 35
Results
###end title 35
###begin p 36
###xml 133 140 133 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 92 95 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 181 184 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
###xml 286 289 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
A total of 233 subjects were enrolled in this study, comprising 118 unrelated patients with PCV and 115 healthy control individuals (Table 1). The mean ages were 65+/-8.4 years for PCV patients and 69+/-8.7 years for healthy controls (p<0.001). The percentage of males was 66.1% in the PCV group and 60% in the control group (p=0.335).
###end p 36
###begin p 37
###xml 176 184 176 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
Four SNPs were chosen as tag SNPs. Genotypes were determined successfully by restriction enzyme digestion in all subjects for the four SNPs and confirmed by direct sequencing (Figure 2). None of the four SNPs genotyped in this study showed significant deviation from Hardy-Weinberg equilibrium tests in both case and control subjects (all p>0.252).
###end p 37
###begin p 38
###xml 127 128 127 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 248 249 248 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 310 311 310 311 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 494 495 494 495 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 615 616 615 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 799 800 799 800 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
PCR restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing for all tag single nucleotide polymorphisms (SNPs). A: Restriction analysis for  resulted in digestible fragment (C/C), undigestible fragment (T/T), and heterozygote (C/T). B: Direct sequencing confirmed the restriction patterns for . C: Restriction analysis for  resulted in digestible fragment (A/A), undigestible fragment (G/G), and heterozygote (A/G). D. Reverse sequencing confirmed the restriction patterns for . E: Restriction analysis for  resulted in digestible fragment (C/C), undigestible fragment (T/T), and heterozygote (C/T). F: Reverse sequencing confirmed the restriction patterns for . G. Restriction analysis for  resulted in digestible fragment (A/A), undigestible fragment (G/G), and heterozygote (A/G). H: Reverse sequencing confirmed the restriction patterns for .
###end p 38
###begin p 39
###xml 140 147 140 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 215 222 215 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 293 300 293 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 305 312 305 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 288 291 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 326 329 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
The minor allele frequencies in each group for all tag SNPs genotyped and the results of the single-SNP association study are summarized in Table 4. The results of genotype frequencies for all tag SNPs are shown in Table 5. None of the four tag SNPs showed a significant association with PCV (Table 4 and Table 5). The OR for PCV in rs2511989 A/G heterozygotes compared with wild-type G/G homozygotes was 1.08 (95% CI 0.60-1.95). A similar comparison of the A/A homozygotes with the wild type yielded an OR of 3.04 (0.31-29.77).
###end p 39
###begin title 40
###xml 52 55 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Association test for minor allele frequency between PCV and control subjects
###end title 40
###begin p 41
###xml 76 79 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Abbreviations: CI represents confidence interval; OR represents odds ratio; PCV represents polypoidal choroidal vasculopathy; SNP represents single nucleotide polymorphism.
###end p 41
###begin title 42
###xml 38 41 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Association test for genotype between PCV and control subjects
###end title 42
###begin p 43
###xml 62 65 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Abbreviations: SNP represents single nucleotide polymorphism; PCV represents polypoidal choroidal vasculopathy; OR represents odds ratio; 95%CI represents 95% confidence intervals. OR and 95%CI were calculated to estimate risk size as comparison of the homozygote and heterozygote versus wild-type homozygote.
###end p 43
###begin p 44
###xml 67 75 67 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 310 317 310 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 268 271 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 385 388 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
The pairwise LD structure was constructed with all SNPs genotyped (Figure 3). Three SNPs, , , and , were placed within one haplotype block, and we examined haplotypes based on these three SNPs in the haplotype block. Details of the haplotypes and their frequencies in PCV and control subjects are presented in Table 6. No particular haplotype was found to be associated with a risk of PCV.
###end p 44
###begin p 45
###xml 83 92 83 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1)</italic>
###xml 365 366 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Linkage disequilibrium structure of serpin peptidase inhibitor, clade G, member 1 (SERPING1). Linkage disequilibrium (LD) was measured using data from all subjects in this study. The haplotype blocks were determined using the "4-gamete rule" option implemented in the Haploview software. Each box provides estimated statistics of the coefficient of determination (r2), with darker shades representing stronger LD.
###end p 45
###begin title 46
Inferred haplotype frequencies and haplotype-based association study
###end title 46
###begin p 47
###xml 63 66 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 190 193 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
All haplotypes with frequency >1% in the combined samples from PCV patients and controls are shown. *Haplotypes were defined by the following three contiguous SNPs: , , and . Abbreviations: PCV represents polypoidal choroidal vasculopathy; OR represents odds ratio; 95%CI represents 95% confidence intervals.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 49 57 49 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 162 170 162 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 77 80 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 192 195 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
In this study we investigated the association of SERPING1 polymorphisms with PCV in a Chinese Han population. Our study showed that none of the four tag SNPs for SERPING1 were associated with PCV. The genotyping methods used in this study were different from those in a previous study [26]. As shown previously [33,34], different genotyping technologies could yield inconsistent genotyping results. To validate the results of genotyping, two methods, PCR restriction fragment length polymorphism and direct sequencing, were used in this study.
###end p 49
###begin p 50
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 0 3 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 166 169 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 371 374 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
PCV shares many similarities with neovascular AMD. However, the histopathological findings remain confusing [35], and there are distinct clinical differences between PCV and neovascular AMD, including morphologic features and disease progression [3], as well as response to therapy [36,37]. The clinical differences may indicate different genetic characteristics between PCV and neovascular AMD.
###end p 50
###begin p 51
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 445 453 445 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 1040 1043 1040 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1045 1046 1045 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1055 1057 1055 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 1086 1094 1086 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 1101 1103 1101 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 1108 1111 1108 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB</italic>
###xml 1113 1115 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 221 224 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 883 886 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
The complement system is a powerful component of innate immunity, which recognizes pathogens and unwanted host material and facilitates their elimination [38]. Activation of complement leading to membrane attack complex (MAC) formation can be triggered via three known pathways (the classical, lectin, and alternative pathways). The classical pathway is generally initiated by antibody interactions with foreign antigens. The protein encoded by SERPING1 is an important complement regulator and plays a crucial part in suppressing the activity of C1. Inhibition of C1 prevents activation of C2 and C4, thus the cleavage of C3 into the anaphylatoxin C3a and the major fragment C3b is inhibited. C3b subsequently binds foreign structures and forms a complex with CFB that cleaves C5 (C3bBb, C5 convertase). This complex amplifies the complement response, resulting in the formation of MAC. Variants within several genes that code for proteins involved in the complement system are recognized to either significantly increase the risk of AMD (CFH [9-11] and C3 [23]) or decrease the risk (SERPING1 [26], C2 and CFB [24]).
###end p 51
###begin p 52
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 408 411 408 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 32 35 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 108 111 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 400 403 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 568 571 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Due to the similarities between PCV and AMD, several studies were conducted to test the association between PCV and complement components. Previous studies [39,40] showed that several CFH variants (, , , , and ) but not the Y402H variant that is the most common variant in western AMD patients, were significantly associated with neovascular AMD in Chinese cohorts. A significant association between PCV and CFH variants ( and ) was observed in another Chinese cohort [18]. Thus it appeared that the alternative pathway might be implicated in the pathogenesis of both PCV and AMD.
###end p 52
###begin p 53
###xml 66 68 66 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 73 75 73 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BF</italic>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 273 281 273 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 315 317 315 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 322 330 322 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 135 138 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 265 268 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 533 536 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 622 625 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
Several studies showed a protective effect on neovascular AMD for C2 and BF [24,41]. However, the association was not observed between PCV and C2 in a Chinese cohort [18]. Ennis [26] reported a protective effect on AMD for SERPING1; however, no association between PCV and SERPING1 was observed in this study. Both C2 and SERPING1 are crucial regulators of the classic complement pathway. Given the published data and the results of this study, we hypothesized that the classic pathway might play a minor role in the pathogenesis of PCV compared with neovascular AMD. However, further studies containing larger numbers of PCV and neovascular AMD patients should be conducted to test our hypotheses.
###end p 53
###begin p 54
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 402 405 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 499 502 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Drusen is abnormal accumulations of extracellular material that forms between the basal surface of the retinal pigmented epithelium and Bruch's membrane. It is a significant risk factor for the development of AMD [42]. Previous studies showed that several complement components were found in drusen, including C3a and C5b-9 [43,44]. The prevalence of large soft drusen in the fellow eyes of unilateral PCV patients was much less than that among AMD patients [5,45]. This clinical difference between PCV and AMD can be partly explained by the genetic differences between them.
###end p 54
###begin p 55
###xml 67 70 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 221 224 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Potential limitations of our study should be mentioned. First, the PCV and control groups were not completely age matched. Second, we did not sample enough neovascular AMD patients and no comparison was conducted between PCV and neovascular AMD in this Chinese Han cohort. Third, no mechanistic and functional evaluations were conducted in this study.
###end p 55
###begin p 56
###xml 76 84 76 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 228 236 228 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 104 107 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 285 288 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 372 375 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
In summary, this study has been conducted to investigate the association of SERPING1 polymorphisms with PCV. To our knowledge, this issue has not been investigated to date. We found no evidence to support the role of any common SERPING1 variation, including , in the susceptibility to PCV in a Chinese Han population; thus the focus may be shifted to other loci in future PCV-related genetic association studies.
###end p 56
###begin title 57
Acknowledgments
###end title 57
###begin p 58
###xml 26 34 <span type="species:ncbi:9606">patients</span>
The authors thank all the patients and family members for their participation. This study was supported by the National Basic Research Program of China (grant number 2007CB512206). The authors have no financial or conflicting interests to disclose.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
###xml 46 50 <span type="species:ncbi:32629?0.2">IPCV</span>
Idiopathic polypoidal choroidal vasculopathy (IPCV).
###end article-title 60
###begin article-title 61
Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration.
###end article-title 61
###begin article-title 62
Polypoidal choroidal vasculopathy.
###end article-title 62
###begin article-title 63
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Subtype lesions of neovascular age-related macular degeneration in Chinese patients.
###end article-title 63
###begin article-title 64
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of exudative age-related macular degeneration in Japanese patients.
###end article-title 64
###begin article-title 65
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration.
###end article-title 65
###begin article-title 66
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
###end article-title 66
###begin article-title 67
Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation.
###end article-title 67
###begin article-title 68
Complement factor H polymorphism and age-related macular degeneration.
###end article-title 68
###begin article-title 69
Complement factor H variant increases the risk of age-related macular degeneration.
###end article-title 69
###begin article-title 70
Complement factor H polymorphism in age-related macular degeneration.
###end article-title 70
###begin article-title 71
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration.
###end article-title 71
###begin article-title 72
CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration.
###end article-title 72
###begin article-title 73
HTRA1 promoter polymorphism in wet age-related macular degeneration.
###end article-title 73
###begin article-title 74
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.
###end article-title 74
###begin article-title 75
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.
###end article-title 75
###begin article-title 76
Association of LOC387715 A69S with vitreous hemorrhage in polypoidal choroidal vasculopathy.
###end article-title 76
###begin article-title 77
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy.
###end article-title 77
###begin article-title 78
Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy.
###end article-title 78
###begin article-title 79
LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population.
###end article-title 79
###begin article-title 80
Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population.
###end article-title 80
###begin article-title 81
###xml 39 47 <span type="species:ncbi:9606">patients</span>
ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy.
###end article-title 81
###begin article-title 82
Complement C3 variant and the risk of age-related macular degeneration.
###end article-title 82
###begin article-title 83
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.
###end article-title 83
###begin article-title 84
Complement 1 inhibitor is a regulator of the alternative complement pathway.
###end article-title 84
###begin article-title 85
Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study.
###end article-title 85
###begin article-title 86
Common variation in the SERPING1 gene is not associated with age-related macular degeneration in two independent groups of subjects.
###end article-title 86
###begin article-title 87
Criteria for diagnosis of polypoidal choroidal vasculopathy.
###end article-title 87
###begin article-title 88
The International HapMap Project.
###end article-title 88
###begin article-title 89
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 89
###begin article-title 90
Detection of congenital color vision defects using heteroduplex-SSCP analysis.
###end article-title 90
###begin article-title 91
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 91
###begin article-title 92
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients.
###end article-title 92
###begin article-title 93
No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
###end article-title 93
###begin article-title 94
Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy.
###end article-title 94
###begin article-title 95
Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula.
###end article-title 95
###begin article-title 96
Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.
###end article-title 96
###begin article-title 97
The complement system: an overview.
###end article-title 97
###begin article-title 98
Association of complement factor H polymorphisms with exudative age-related macular degeneration.
###end article-title 98
###begin article-title 99
Multiple gene polymorphisms in the complement factor h gene are associated with exudative age-related macular degeneration in chinese.
###end article-title 99
###begin article-title 100
Analysis of rare variants in the complement component 2 (C2) and factor B (BF) genes refine association for age-related macular degeneration (AMD).
###end article-title 100
###begin article-title 101
Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser photocoagulation-induced regression.
###end article-title 101
###begin article-title 102
Complement activation and inflammatory processes in drusen formation and age related macular degeneration.
###end article-title 102
###begin article-title 103
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration.
###end article-title 103
###begin article-title 104
Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population.
###end article-title 104

